Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by KalVista Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
Next >
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
March 12, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
March 10, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
March 03, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
February 24, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
February 21, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
February 10, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
January 21, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2025
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Appoints Jeb Ledell as Chief Operating Officer
December 16, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
December 05, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
November 26, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 12, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
November 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
November 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
October 28, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
October 18, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
October 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
September 30, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
September 26, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Appoints Brian Piekos as Chief Financial Officer
September 10, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
September 06, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
September 05, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
September 03, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.